HOXC9 and hepatocellular carcinoma: The expression of HOXC9, D10, and D11 were positively correlated with the IC50 of lenvatinib (Figure 10(b)), which was the first new drug approved for advanced stage HCC in the first-line setting in over 10 years [36].